Melatonin Inhibits EMT in Bladder Cancer by Targeting Autophagy

Area of Science:

• Oncology
• Biochemistry

Background:

• Melatonin, a pineal gland hormone, demonstrates broad antitumor activities.
• Its known mechanisms include apoptosis induction, antimetastatic effects, and immune surveillance restoration.
• Clinical evidence for melatonin in bladder cancer is limited.

Purpose of the Study:

• To investigate the effects of melatonin on bladder cancer cell migration and epithelial-mesenchymal transition (EMT).
• To explore the role of autophagy in melatonin's action on bladder cancer cells.
• To evaluate melatonin's in vivo antitumor efficacy in an orthotopic bladder cancer model.

Main Methods:

• In vitro assessment of bladder cancer cell migration and EMT markers.
• Analysis of autophagy levels in melatonin-treated bladder cancer cells.
• In vivo study using an orthotopic animal model of bladder cancer.

Main Results:

• Melatonin treatment significantly suppressed bladder cancer cell migration by inhibiting EMT.
• Melatonin-induced decreases in autophagy were observed in bladder cancer cells.
• In vivo, melatonin administration slightly prolonged the survival of tumor-bearing mice.

Conclusions:

• Melatonin exhibits antimigratory effects on bladder cancer cells, potentially via EMT inhibition and autophagy modulation.
• Melatonin shows modest antitumor activity in an in vivo bladder cancer model.
• Further research into melatonin as a bladder cancer therapeutic is warranted.